ReviewYonsei medical journal2009
Promoter methylation in the genesis of gastrointestinal cancer.
Review in Yonsei medical journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Magnetic hyperthermia in oncology: Nanomaterials-driven combinatorial strategies for synergistic therapeutic gains.Materials today. Bio · 2025Review
- Role of PLK4 inhibition in cancer therapy.Cancer metastasis reviews · 2025Review
- Case report: Two cases of pyloric adenomas with high-grade intraepithelial neoplasia at distinct locations.Frontiers in immunology · 2024Article
- Lack of Aberrant Methylation in an Adjacent Area of Left-Sided Colorectal Cancer.Yonsei medical journal · 2017Article
- Extramural vascular invasion and response to neoadjuvant chemoradiotherapy in rectal cancer: Influence of the CpG island methylator phenotype.World journal of gastrointestinal oncology · 2017Article
- Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma.World journal of gastroenterology · 2015Review
- Development of a gLCR-based KRAS mutation detection approach and its comparison with other screening methods.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Clinical implications of microsatellite instability in T1 colorectal cancer.Yonsei medical journal · 2015Article
- Review of the development of DNA methylation as a marker of response to neoadjuvant therapy and outcomes in rectal cancer.Clinical epigenetics · 2015Article
- DNA methylation and microRNAs in cancer.World journal of gastroenterology · 2012Review
- Epigenetics: principles and practice.Digestive diseases (Basel, Switzerland) · 2011Review
- DNA methylation changes in ex-adenoma carcinoma of the large intestine.Virchows Archiv : an international journal of pathology · 2010Article
- All y'all need to know 'bout retroelements in cancer.Seminars in cancer biology · 2010Review
- Nitric oxide: perspectives and emerging studies of a well known cytotoxin.International journal of molecular sciences · 2010Review
- Microsatellite instability in colorectal cancer.Gastroenterology · 2010Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
Abstract
Colorectal cancers (CRC)--and probably all cancers--are caused by alterations in genes. This includes activation of oncogenes and inactivation of tumor suppressor genes (TSGs). There are many ways to achieve these alterations. Oncogenes are frequently activated by point mutation, gene amplification, or changes in the promoter (typically caused by chromosomal rearrangements). TSGs are typically inactivated by mutation, deletion, or promoter methylation, which silences gene expression. About 15% of CRC is associated with loss of the DNA mismatch repair system, and the resulting CRCs have a unique phenotype that is called microsatellite instability, or MSI. This paper reviews the types of genetic alterations that can be found in CRCs and hepatocellular carcinoma (HCC), and focuses upon the epigenetic alterations that result in promoter methylation and the CpG island methylator phenotype (CIMP). The challenge facing CRC research and clinical care at this time is to deal with the heterogeneity and complexity of these genetic and epigenetic alterations, and to use this information to direct rational prevention and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.